Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Raltegravir
Drug ID BADD_D01905
Description Raltegravir is an antiretroviral drug produced by Merck & Co., used to treat HIV infection. It received approval by the U.S. Food and Drug Administration (FDA) on 12 October 2007, the first of a new class of HIV drugs, the integrase inhibitors, to receive such approval.
Indications and Usage For the treatment of HIV-1 infection in conjunction with other antiretrovirals.
Marketing Status approved
ATC Code J05AJ01
DrugBank ID DB06817
KEGG ID D06676
MeSH ID D000068898
PubChem ID 54671008
TTD Drug ID D0I1FQ
NDC Product Code 0006-0477; 0006-3603; 50090-1085; 65977-0049; 82982-055; 17381-749; 0006-0227; 53002-1686; 71205-777; 68071-2113; 0006-3080; 0006-0473
UNII 22VKV8053U
Synonyms Raltegravir Potassium | Potassium, Raltegravir | Raltegravir | MK 0518 | 0518, MK | MK0518 | MK-0518 | Isentress
Chemical Information
Molecular Formula C20H21FN6O5
CAS Registry Number 518048-05-0
SMILES CC1=NN=C(O1)C(=O)NC(C)(C)C2=NC(=C(C(=O)N2C)O)C(=O)NCC3=CC=C(C=C3)F
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain07.01.05.002--
Abortion spontaneous18.01.04.0010.018129%Not Available
Agranulocytosis01.02.03.0010.002472%Not Available
Anaphylactic shock24.06.02.004; 10.01.07.0020.001648%Not Available
Anxiety19.06.02.002--
Aortic aneurysm24.02.03.0010.001648%Not Available
Apnoea22.02.01.0010.001648%
Arrhythmia02.03.02.0010.003296%Not Available
Ascites07.07.01.001; 02.05.04.002; 09.01.05.0030.001648%
Asthenia08.01.01.001--Not Available
Cerebellar ataxia17.02.02.013; 08.01.02.006--Not Available
Cerebellar syndrome17.02.02.0020.002472%Not Available
Cholestasis09.01.01.0010.002472%Not Available
Chorea17.01.01.0010.001648%Not Available
Coma17.02.09.0010.003626%Not Available
Completed suicide19.12.01.001; 08.04.01.0100.002472%Not Available
Cyst08.03.05.001; 16.02.02.0020.001648%Not Available
Depression19.15.01.0010.010548%
Dermatitis allergic23.03.04.003; 10.01.03.0140.001648%Not Available
Diabetes mellitus05.06.01.001; 14.06.01.0010.007252%Not Available
Diarrhoea07.02.01.0010.054058%
Dizziness02.11.04.006; 24.06.02.007; 17.02.05.003--
Drug eruption10.01.01.005; 08.01.06.015; 23.03.05.0010.008900%Not Available
Drug interaction08.06.03.0010.014174%Not Available
Dyspepsia07.01.02.001--
Dysphagia07.01.06.0030.071857%
Dystonia17.01.03.0010.001648%Not Available
Embolic stroke24.01.04.010; 17.08.01.0320.001648%Not Available
Eosinophilia01.02.04.0010.004120%
Face oedema23.04.01.004; 10.01.05.002; 08.01.07.0030.003296%
The 1th Page    1 2 3 4 5    Next   Last    Total 6 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene